Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 17.49
(-2.02%)
CNY 17.49
(-2.02%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 57.55 Million CNY | -60.33% |
| 2022 | 145.08 Million CNY | 15.38% |
| 2021 | 125.74 Million CNY | 59.71% |
| 2020 | 78.73 Million CNY | 3.25% |
| 2019 | 76.25 Million CNY | 28.53% |
| 2018 | 59.33 Million CNY | -3.09% |
| 2017 | 61.22 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 2.98 Million CNY | -93.27% |
| 2024 Q3 | -4.15 Million CNY | -238.87% |
| 2024 Q1 | 44.43 Million CNY | 451.74% |
| 2023 Q2 | 4.33 Million CNY | -93.74% |
| 2023 FY | 57.55 Million CNY | -60.33% |
| 2023 Q4 | -12.63 Million CNY | -269.42% |
| 2023 Q3 | -3.41 Million CNY | -178.9% |
| 2023 Q1 | 69.27 Million CNY | 107.95% |
| 2022 Q3 | -5.2 Million CNY | -120.62% |
| 2022 Q2 | 25.22 Million CNY | -72.51% |
| 2022 Q1 | 91.75 Million CNY | 47.96% |
| 2022 FY | 145.08 Million CNY | 15.38% |
| 2022 Q4 | 33.31 Million CNY | 740.62% |
| 2021 FY | 125.74 Million CNY | 59.71% |
| 2021 Q4 | 62.01 Million CNY | 1185.88% |
| 2021 Q3 | -5.71 Million CNY | -124.98% |
| 2021 Q2 | 22.86 Million CNY | -50.91% |
| 2021 Q1 | 46.57 Million CNY | 69.75% |
| 2020 FY | 78.73 Million CNY | 3.25% |
| 2020 Q4 | 27.43 Million CNY | 320.09% |
| 2020 Q3 | -12.46 Million CNY | -160.62% |
| 2020 Q2 | 20.56 Million CNY | -52.39% |
| 2020 Q1 | 43.19 Million CNY | 0.0% |
| 2019 FY | 76.25 Million CNY | 28.53% |
| 2018 FY | 59.33 Million CNY | -3.09% |
| 2017 FY | 61.22 Million CNY | 0.0% |